Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 7, 2016, Pages 1336-1337

  Bruce, Ellen S ^a   Kearsley Fleet, Lianne ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a,b   Hyrich, Kimme L ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LETTER; LUNG DISEASE; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; REGISTER;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84977083836     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew200     Document Type: Letter

References (6)

1. Garcia-Doval I, Perez-Zafrilla B, Descalzo MA et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69:1751-5.
2. Galloway JB, Mercer LK, Moseley A et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013;72:229-34.
3. Slifman NR, Gershon SK, Lee J-H, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritis Rheum 2003;48:319-24.
4. Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
5. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94.
6. Walzer PD, Evans HER, Copas AJ et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIVinfected patients: 1985-2006. Clin Infect Dis 2008;46:625-33.